8-May-2025	NYR-BI03 Extends Cardioprotection to Arrhythmia Control

2-May-2025	Phase I Clinical Trial Dosing Update No 2

17-Apr-2025	Results of Meeting

15-Apr-2025	Quarterly Activities Report and Appendix 4C

9-Apr-2025	Notice of Initial Substantial Holder - M Azzi

9-Apr-2025	Phase I Clinical Trial Dosing Update No 1

7-Apr-2025	Significant Neuroprotection in Traumatic Brain Injury Study

31-Mar-2025	First Cohort Dosed in Nyradas Phase I Clinical Trial

17-Mar-2025	Nyrada Commences Phase I Clinical Trial Recruitment

12-Mar-2025	2025 EGM Letter to Shareholders, Notice of Meeting and Proxy

18-Feb-2025	Nyrada Half Year Results FY2025

18-Feb-2025	Appendix 4D and Half Year Report to 31 December 2024

7-Feb-2025	Nyrada to Commence Phase Ia Clinical Trial

23-Jan-2025	Quarterly Activities Report and Appendix 4C

23-Jan-2025	Change of Director's Interest Notice - JM

22-Jan-2025	Change of Director's Interest Notice - MF

22-Jan-2025	Change of Director's Interest Notice - RW

22-Jan-2025	Change of Director's Interest Notice - CC

21-Jan-2025	Change of Director's Interest Notice - ID

21-Jan-2025	Notification of cessation of securities - NYR

31-Dec-2024	NYR-BI03 Phase Ia Clinical Trial Update 2

24-Dec-2024	Nyrada Receives A$1.235M R&D Tax Incentive Rebate

23-Dec-2024	Upcoming Expiry of Unlisted Warrants

17-Dec-2024	NYR-BI03 Phase Ia Clinical Trial Update - Correction

16-Dec-2024	NYR-BI03 Phase Ia Clinical Trial Update

9-Dec-2024	Application for quotation of securities - NYR

6-Dec-2024	Securities Purchase Plan Closure

25-Nov-2024	Investor Presentation

25-Nov-2024	Nyrada Investor Conference Call Reminder

14-Nov-2024	Change of Director's Interest Notice - GM

14-Nov-2024	Notification regarding unquoted securities - NYR

12-Nov-2024	Nyrada Annual General Meeting Results

12-Nov-2024	CEO AGM Presentation

12-Nov-2024	Nyrada AGM 2024 Chair Address

11-Nov-2024	Change of Registered Office and Principal Place of Business

8-Nov-2024	Nyrada Investor Conference Call

5-Nov-2024	Notice of Change of Interests of a Sub Securityholder

5-Nov-2024	Notice of Ceasing to be a Substantial Securityholder

5-Nov-2024	2024 AGM Addendum to the Notice of Meeting and Proxy

4-Nov-2024	Cleansing Statement

4-Nov-2024	Application for quotation of securities - NYR

4-Nov-2024	Notification regarding unquoted securities - NYR

4-Nov-2024	Update - Proposed issue of securities - NYR

4-Nov-2024	Securities Purchase Plan Offer Booklet

4-Nov-2024	Cleansing Notice for Security Purchase Plan

28-Oct-2024	Proposed issue of securities - NYR

28-Oct-2024	Proposed issue of securities - NYR

28-Oct-2024	Investor Presentation

28-Oct-2024	Nyrada Successfully Raises $3.36 Million via Placement

24-Oct-2024	Trading Halt

24-Oct-2024	Quarterly Activities Report and Appendix 4C

23-Oct-2024	Supplementary NYR-BI03 Study Confirm Strong Cardioprotection

16-Oct-2024	NYR Completes Safety Studies Ahead of Phase I Clinical Trial

7-Oct-2024	Brain Injury Program GLP Studies Further Update 6

4-Oct-2024	Investor Presentation

1-Oct-2024	Drug Candidate Demonstrates Significant Cardioprotection

1-Oct-2024	Trading Halt

1-Oct-2024	Pause in Trading

30-Sep-2024	2024 Annual General Meeting Access Letter, Notice and Proxy

27-Sep-2024	Brain Injury Program GLP Studies Further Update 5

17-Sep-2024	Investor Presentation

9-Sep-2024	Brain Injury Program GLP Studies Further Update 4

22-Aug-2024	Full Year Results FY2024

22-Aug-2024	Annual Report for year ended 30 June 2024

22-Aug-2024	Preliminary final report

22-Aug-2024	Appendix 4G and Corporate Governance Statement

20-Aug-2024	Brain Injury Program GLP Studies Further Update No 3

15-Aug-2024	Investor Presentation

6-Aug-2024	Brain Injury Program GLP Studies Further Update

16-Jul-2024	GLP Studies Update

9-Jul-2024	Nyrada Quarterly Activities Report & Appendix 4C

1-Jul-2024	Notification of cessation of securities - NYR

26-Jun-2024	NYR Signs Strategic Partnership with US Brain Injury Company

12-Jun-2024	Change of Director's Interest Notice - JM

12-Jun-2024	Change of Director's Interest Notice - RW

12-Jun-2024	Change of Director's Interest Notice - MF

12-Jun-2024	Change of Director's Interest Notice - ID

12-Jun-2024	Notification regarding unquoted securities - NYR

12-Jun-2024	Cleansing Statement

12-Jun-2024	Application for quotation of securities - NYR

27-May-2024	Upcoming Expiry of Unlisted Warrants

16-May-2024	Nyrada General Meeting Results

30-Apr-2024	Nyrada Commences Walter Reed Traumatic Brain Injury Study

18-Apr-2024	Investor Presentation - April 2024

11-Apr-2024	3QFY2024 Results and Investor Conference Call

10-Apr-2024	Quarterly Activities Report and Appendix 4C

2-Apr-2024	2024 EGM Letter to Shareholders and Proxy

2-Apr-2024	2024 EGM Notice of Meeting and Proxy

28-Mar-2024	Nyrada Commences Key Brain Injury Program Preclinical Study

15-Mar-2024	Notice of Change of Interests of Substantial Securityholder

15-Mar-2024	Notice of Change of Interests of Substantial Securityholder

15-Mar-2024	Cleansing Statement

15-Mar-2024	Application for quotation of securities - NYR

15-Mar-2024	Amended and Restated Certificate of Incorporation and Bylaw

14-Mar-2024	Change of Director's Interest Notice - CC

14-Mar-2024	Change of Director's Interest Notice - RW

14-Mar-2024	Change of Director's Interest Notice - MF

14-Mar-2024	Change of Director's Interest Notice - JM

14-Mar-2024	Notification of cessation of securities - NYR

6-Mar-2024	Nyrada Successfully Raises $1.755 Million via Placement

6-Mar-2024	Proposed issue of securities - NYR

6-Mar-2024	Proposed issue of securities - NYR

4-Mar-2024	Trading Halt

28-Feb-2024	Nyrada CEO James Bonner interview with 180 Markets

28-Feb-2024	Significant Neuroprotection in NYR Preclinical Brain Injury

20-Feb-2024	Nyrada Half Year Results FY2024

20-Feb-2024	Appendix 4D and Half Year Report to 31 December 2023

19-Jan-2024	Amended and Restated Certificate of Incorporation and Bylaws

17-Jan-2024	Quarterly Activities Report and Appendix 4C

8-Dec-2023	Nyrada Receives A$3.54M R&D Tax Incentive Rebate

20-Nov-2023	Nyrada Annual General Meeting Results

20-Nov-2023	Nyrada AGM 2023 CEO Presentation

20-Nov-2023	Nyrada AGM 2023 Chair Address

1-Nov-2023	2023 AGM Chair Letter to Shareholders

17-Oct-2023	2023 AGM Notice of Meeting and Proxy

17-Oct-2023	2023 AGM Letter to Shareholders and Proxy

13-Oct-2023	Quarterly Activities Report and Appendix 4C

28-Aug-2023	Nyrada Full Year Results FY2023

28-Aug-2023	Annual Report for year ended 30 June 2023

28-Aug-2023	Preliminary Final Report

28-Aug-2023	Appendix 4G and Corporate Governance Statement

28-Jul-2023	Quarterly Activities Report and Appendix 4C

20-Jul-2023	Nyrada Review of Operating Costs

26-Jun-2023	Cholesterol-Lowering Program Update

9-Jun-2023	Brain Injury Program Preclinical Development Update

26-May-2023	Cholesterol-Lowering Program Preclinical Studies Completed

26-Apr-2023	Quarterly Activities Report and Appendix 4C

11-Apr-2023	Cholesterol-Lowering Program Preclinical Development Update

24-Feb-2023	Nyrada Half Year Results FY2023

24-Feb-2023	Appendix 4D and Half Year Report to 31 December 2022

30-Jan-2023	Quarterly Activities Report and Appendix 4C

18-Jan-2023	Collaboration with Walter Reed and UNSW Extended to 2025

16-Jan-2023	Notification of cessation of securities - NYR

11-Jan-2023	Brain Injury Program Update

21-Nov-2022	Results of Meeting

21-Nov-2022	AGM Presentation by James Bonnar CEO

21-Nov-2022	Nyrada AGM 2022 Chairmans Address

18-Nov-2022	Nyrada Receives A$1.2M R&D Tax Incentive Rebate

27-Oct-2022	CEO Remuneration Update

26-Oct-2022	Quarterly Activities Report and Appendix 4C

18-Oct-2022	2022 AGM Letter to Shareholders and Proxy

18-Oct-2022	2022 AGM Notice of Meeting and Proxy

10-Oct-2022	Efficacy Study Published in Journal of Lipid Research

29-Sep-2022	Presentation to ShareCafe Hidden Gems Webinar

5-Sep-2022	Presentation to E&P Small Caps Health Care Conference

29-Aug-2022	Nyrada Reports Full Year FY2022 Results

29-Aug-2022	Annual Report to June 30 2022

29-Aug-2022	Preliminary Final Report

29-Aug-2022	Appendix 4G and Corporate Governance Statement

2-Aug-2022	Nyrada Board Changes

2-Aug-2022	Initial Director's Interest Notice - GM

2-Aug-2022	Final Director's Interest Notice - PM

26-Jul-2022	Quarterly Activities Report and Appendix 4C

20-Jul-2022	Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis

29-Jun-2022	Cholesterol-Lowering Program Update

7-Jun-2022	Corporate Presentation

6-Jun-2022	Brain Injury Program Target Unveiled and Phase I Update

17-May-2022	European Patent to be Granted for Cholesterol-Lowering Drug

19-Apr-2022	Nyrada Quarterly Activities Report & Appendix 4C

30-Mar-2022	Investor Roadshow Presentation

29-Mar-2022	New Drug Offers Potential Oral Treatment for Concussion

2-Mar-2022	Presentation to Meet the CEO Life Sciences Edition

25-Feb-2022	Nyrada Half Year Results FY2022

25-Feb-2022	Appendix 4D and Half Year Report to 31 December 2021

21-Jan-2022	Nyrada Quarterly Activities Report & Appendix 4C

17-Jan-2022	Application for quotation of securities - NYR

17-Jan-2022	Change of Director's Interest Notice - ID

17-Jan-2022	Change of Director's Interest Notice - MF

17-Jan-2022	Change of Director's Interest Notice - RW

17-Jan-2022	Change of Director's Interest Notice - JM

17-Jan-2022	Change of Director's Interest Notice - CC

17-Jan-2022	Change of Director's Interest Notice - PM

12-Jan-2022	Nyrada Receives A$1.3M R&D Tax Incentive Rebate

4-Jan-2022	Brain Injury Program Update and Pathway to Phase I

22-Dec-2021	Cholesterol-Lowering Program Pathway to Phase I

10-Dec-2021	Release of Securities from Escrow

19-Nov-2021	Nyrada Annual General Meeting Results

19-Nov-2021	Annual General Meeting Presentation

19-Nov-2021	Nyrada AGM 2021 Chairman's Address

26-Oct-2021	Nyrada Quarterly Activities Report & Appendix 4C

19-Oct-2021	2021 AGM Notice of Meeting and Proxy

19-Oct-2021	2021 AGM Letter to Shareholders and Proxy

13-Sep-2021	Presentation to ASX Small and Mid-Cap Conference

3-Sep-2021	Updated Share Trading Policy

30-Aug-2021	Nyrada Reports Full Year FY2021 Results

30-Aug-2021	Annual Report to 30 June 2021

30-Aug-2021	Preliminary Final Report

30-Aug-2021	Appendix 4G and Corporate Governance Statement

13-Aug-2021	NYX-PCSK9i In Vivo Study Exploratory Analysis Results

30-Jul-2021	Nyrada Announces US Patent Grant for PCSK9 Inhibitor

27-Jul-2021	Nyrada Quarterly Activities Report & Appendix 4C

30-Jun-2021	Change of Director's Interest Notice - CC

30-Jun-2021	Change of Director's Interest Notice - ID

30-Jun-2021	Change of Director's Interest Notice - RW

30-Jun-2021	Change of Director's Interest Notice - MF

30-Jun-2021	Change of Director's Interest Notice - PM

30-Jun-2021	Change of Director's Interest Notice - JM

30-Jun-2021	Change in substantial holding

30-Jun-2021	Change in substantial holding

29-Jun-2021	Cleansing Statement

29-Jun-2021	Confirmation of Capital Structure, CDIs on Issue

29-Jun-2021	Notification regarding unquoted securities - NYR

29-Jun-2021	Application for quotation of securities - NYR

29-Jun-2021	Application for quotation of securities - NYR

29-Jun-2021	NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction

16-Jun-2021	Results of Meeting

15-Jun-2021	Improved Drug Candidate Selected for WRAIR Studies

11-May-2021	Notice of Extraordinary General Meeting/Proxy Form

6-May-2021	Nyrada Receives A$1.0M R&D Tax Incentive Rebate

5-May-2021	NYR Announces New Potent Cholesterol-Lowering Candidates

26-Apr-2021	Change of Registered Office and Principal Place of Business

20-Apr-2021	Nyrada Quarterly Activities Report & Appendix 4C

30-Mar-2021	Change in substantial holding

30-Mar-2021	Ceasing to be a substantial holder

30-Mar-2021	Change in substantial holding

30-Mar-2021	Cleansing Statement

30-Mar-2021	Appendix 2A

25-Mar-2021	Change in substantial holding

22-Mar-2021	Proposed issue of Securities - NYR

22-Mar-2021	Nyrada Receives Firm Commitments to Raise A$11 Million

18-Mar-2021	Nyrada Investor Presentation

17-Mar-2021	Trading Halt

5-Mar-2021	Change of Director's Interest Notice - JM

2-Mar-2021	Nyrada Newsletter February 2021

24-Feb-2021	Appendix 3G

24-Feb-2021	Change of Director's Interest Notice - MF

23-Feb-2021	Investor Presentation to Finance News Network CEO Showcase

22-Feb-2021	Nyrada Reports Half Year FY2021 Results

22-Feb-2021	Appendix 4D and Half Year Accounts

16-Feb-2021	Lapsing of balance of Unlisted SAB Options

16-Feb-2021	Cleansing Statement

16-Feb-2021	Appendix 2A

1-Feb-2021	NYR Secures Collaboration with Walter Reed and UNSW

29-Jan-2021	Trading Halt

28-Jan-2021	Nyrada Quarterly Activities Report & Appendix 4C

25-Jan-2021	Nyrada Reports Further Results from Cholesterol Study

22-Jan-2021	Unlisted Scientific Advisory Board Options Expiry 15 Feb 21

18-Jan-2021	Change of Director's Interest Notice - ID

18-Jan-2021	Appendix 3G

18-Jan-2021	Appendix 3G

18-Jan-2021	Appendix 3G

7-Jan-2021	Release of Securities from Escrow

6-Jan-2021	Change in substantial holding

21-Dec-2020	57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study

14-Dec-2020	Appointment of New Auditor

8-Dec-2020	Change in substantial holding

2-Dec-2020	Cleansing Statement

2-Dec-2020	Appendix 2A

26-Nov-2020	Change of Director's Interest Notice - JM

25-Nov-2020	Change of Director's Interest Notice - MF

25-Nov-2020	Appendix 2A

19-Nov-2020	Nyrada Annual General Meeting Results

19-Nov-2020	Presentation to 2020 Annual General Meeting of Shareholders

19-Nov-2020	Nyrada AGM 2020 Chairmans Address

16-Nov-2020	Release of Securities from Escrow

9-Nov-2020	Unlisted Convertible Note Options Expiring 30 November 2020

3-Nov-2020	2020 Annual General Meeting Reminder

19-Oct-2020	Letter to Shareholders and Proxy Form in relation to AGM

19-Oct-2020	Notice of Annual General Meeting and Proxy Form

13-Oct-2020	Nyrada Quarterly Activities Report & Appendix 4C

24-Sep-2020	Nyrada Newsletter September 2020

17-Sep-2020	Notification of Date of 2020 Annual General Meeting

11-Sep-2020	Change of Director's Interest Notice - JM

11-Sep-2020	Corporate Presentation for ShareCafe Hidden Gems Webinar

9-Sep-2020	Nyrada Investor Webinar

8-Sep-2020	Initial Director's Interest Notice - ID

8-Sep-2020	Final Director's Interest Notice - GK

8-Sep-2020	Annual Report to 30 June 2020

8-Sep-2020	Appendix 4G and Corporate Governance Statement

31-Aug-2020	FY 2020 Appendix 4E Preliminary Financial Report

31-Aug-2020	Nyrada Board Changes

30-Jul-2020	Nyrada Global Webcast Invitation

29-Jul-2020	Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure

23-Jul-2020	Nyrada Roadshow Corporate Presentation

22-Jul-2020	Appendix 4C - June 2020 Quarterly Report

15-Jul-2020	Nyrada Brain Injury Drug Pharmacokinetic Study Results

9-Jul-2020	Nyrada Brain Injury Data Published by Premier US Military Health Conference

8-Jul-2020	Change in substantial holding

6-Jul-2020	Nyrada Cholesterol-Lowering Drug Study Results

25-Jun-2020	Nyrada Newsletter June 2020

24-Jun-2020	Corporate Presentation for the Reach Markets Virtual Event

25-May-2020	Milestone Achieved in the Nyrada Brain Injury Program

30-Apr-2020	Nyrada Preclinical Program & Corporate Update Presentation

27-Apr-2020	Change of Director's Interest Notice - JM

22-Apr-2020	Appointment of New Chief Financial Officer

20-Apr-2020	Preclinical Program & Corporate Update Global Webinar

14-Apr-2020	Appendix 4C - March 2020 quarterly

6-Apr-2020	Nyrada Newsletter Released

16-Mar-2020	Update on Progress in Nyrada Programs

27-Feb-2020	Nyrada Inc. Corporate Presentation February 2020

25-Feb-2020	Appendix 4D and Half Year Accounts

11-Feb-2020	Significant advance in Nyrada PCSK9i program published

20-Jan-2020	Nyrada Inc - Chairman's letter to shareholders

20-Jan-2020	Becoming a substantial holder

17-Jan-2020	Nyrada Inc - Corporate Presentation

16-Jan-2020	NOX: Listing of Nyrada Inc. spin-off on ASX

16-Jan-2020	NYR Commences Trading on the ASX

16-Jan-2020	Becoming a substantial holder

16-Jan-2020	Becoming a substantial holder

16-Jan-2020	Initial Director's Interest Notice

16-Jan-2020	Initial Director's Interest Notice

16-Jan-2020	Initial Director's Interest Notice

16-Jan-2020	Initial Director's Interest Notice

16-Jan-2020	Initial Director's Interest Notice

16-Jan-2020	Initial Director's Interest Notice

15-Jan-2020	Regulation S-Foreign Ownership Restrictions

14-Jan-2020	Confirmation and Waiver under ASX Listing Rules

14-Jan-2020	Pre-Quotation Disclosure

14-Jan-2020	Updated Pro-forma - Financial Position and Commitments

14-Jan-2020	Securities Trading Policy

14-Jan-2020	Capital Structure and Restricted Securities

14-Jan-2020	Financial Statements Year End 30 June 2019

14-Jan-2020	Financial Statements Year End 30 June 2018

14-Jan-2020	Corporate Governance Statement

14-Jan-2020	Equity Incentive Plan

14-Jan-2020	Amended and Restated Certificate of Incorporation and Bylaws

14-Jan-2020	Supplementary Prospectus

14-Jan-2020	Prospectus

14-Jan-2020	Appendix 1A, Information Form and Checklist, Annexure 3

14-Jan-2020	Distribution Schedule

14-Jan-2020	Top 20 Securityholders

14-Jan-2020	ASX Market Release - Admission and Quotation